Remus Pharmaceuticals Ltd

Remus Pharmaceuticals Ltd

₹ 6,507 -2.76%
21 Feb - close price
About

Incorporated in 2015, Remus Pharmaceuticals Limited is engaged in the marketing and distributing of finished formulations of pharmaceutical drugs.[1]

Key Points

Business Segments
A) APIs (84.5% of FY22 revenue)[1] Co has 54 products in this segment
B) Finished Pharmaceutical Formulations(15.5% of FY22 revenue)[1]

  • Market Cap 958 Cr.
  • Current Price 6,507
  • High / Low 7,895 / 1,711
  • Stock P/E 78.3
  • Book Value 500
  • Dividend Yield 0.03 %
  • ROCE 68.8 %
  • ROE 66.1 %
  • Face Value 10.0

Pros

  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 63.6%
  • Debtor days have improved from 51.3 to 39.3 days.
  • Promoter holding has increased by 1.24% over last quarter.

Cons

  • Stock is trading at 13.0 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Half Yearly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Sep 2022 Mar 2023 Sep 2023
14 20 25 29
12 16 19 20
Operating Profit 2 5 6 9
OPM % 11% 23% 23% 32%
1 1 1 2
Interest 0 0 0 0
Depreciation 0 0 0 0
Profit before tax 2 6 6 10
Tax % 29% 27% 25% 25%
1 4 4 8
EPS in Rs 14.40 40.70 40.83 53.02
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
12 18 25 45 54
12 18 21 34 39
Operating Profit 0 1 4 11 15
OPM % 3% 4% 17% 23% 28%
1 1 1 2 2
Interest 0 0 0 0 0
Depreciation 0 0 0 0 1
Profit before tax 1 1 5 11 16
Tax % 27% 25% 26% 26%
1 1 3 8 12
EPS in Rs 810.00 1,060.00 34.30 78.34 93.85
Dividend Payout % 0% 0% 0% 3%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 56%
TTM: 56%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 119%
TTM: 122%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 64%
Last Year: 66%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 0 0 1 1 1
Reserves 2 3 6 18 72
0 0 0 8 2
3 8 9 8 12
Total Liabilities 5 11 16 35 88
0 0 0 3 3
CWIP 0 0 0 0 0
Investments 0 0 3 21 21
5 11 12 11 64
Total Assets 5 11 16 35 88

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023
1 -0 5 5
-1 -0 -5 -15
0 -0 -0 12
Net Cash Flow 1 -0 0 2

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 50 71 43 39
Inventory Days 23 36 47 5
Days Payable 68 164 139 60
Cash Conversion Cycle 5 -56 -48 -16
Working Capital Days 22 -18 -38 8
ROCE % 46% 92% 69%

Shareholding Pattern

Numbers in percentages

Sep 2023
69.61%
2.38%
0.71%
27.30%
No. of Shareholders 856

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents